Advances in Metastatic Castration-Resistant Prostate Cancer

Video

A specialist describes the advances being made in metastatic prostate cancer and provides some clinical pearls for community oncologists.

Matthew Fowler: Lastly, I want to focus in on treatment considerations and future directions. Is patient access a factor in considering the best treatment?

Oliver Sartor, MD: Absolutely. I hate to say it, but 1 thing we’re always dealing with is the ability for insurance to pay for the drugs; they’re all expensive. We must work carefully with the insurance companies and work through precertifications with the insurance companies to ensure that we have the indication right for the patient. At times, we must submit the actual data, and say, “This guy has a germline BRCA2 mutation. Here’s the result. Here are his prior treatments. He’s already progressed on abiraterone. He’s an ideal candidate. He has metastatic castration-resistant prostate cancer [CRPC].” We send all that in and then work it through the precertification process. Absolutely, the reimbursement is a significant issue, and the co-pays can be problematic for patients as well. Sometimes, there are programs that can help. It depends on the individual patient, their financial resources, their insurance resources, and at times, how hard we work the system too. There are a lot of factors that go into choosing the therapy beyond simple indication.

Matthew Fowler: Given all the options now for men with metastatic CRPC, what’s your preferred sequencing strategy?

Oliver Sartor, MD: I’m using hormones first—abiraterone, enzalutamide, maybe darolutamide or apalutamide if they’re not metastatic. I’m trying to get in the novel hormones first because we have an accumulation of data that earlier use of these novel hormones results in better survival advantages. In fact, we have lots of new data that demonstrate that in the castration-sensitive space, if you’re treating with these novel hormones, you do have an amazing effect on overall survival. I try to get my novel hormones as early as I can.

After you fail novel hormones, it gets to be a bit of a Wild West out there because there are many options available. At that point, I’m looking at those genomics and precision therapies that might be available. I’m looking for things like the mismatch repair. That’s where olaparib would come in, not rucaparib because that’s post-taxane. I’ve got olaparib and then pembrolizumab that are for specific patients based on the NGS [next-generation sequencing], the germline testing.

Then I’ve got taxanes—radium and sipuleucel-T—that I might throw in. One of my most common choices is the taxane docetaxel. By the way, I tend to like the 50 mg/m2 every 2 weeks, which isn’t FDA approved. However, there’s a beautiful trial coming out of Finland and headed by a good investigator who demonstrated that the 50 mg/m2 docetaxel, probably a little better tolerated and maybe a little more effective than the 75 mg/m2 every 3 weeks; there’s a bit of an artistic element there. Then we also have the clinical trials to consider. Those are important as well.

Matthew Fowler: Looking ahead, what other exciting advances are being made in metastatic CRPC?

Oliver Sartor, MD: I mentioned the Lutetium-177 PSMA [prostate-specific membrane antigen]. That’s the next FDA approval; it’s pretty clear. There are a series of combination trials using the PARP inhibitors, including 1 I haven’t mentioned called talazoparib, to be put together in combination with the novel hormones, either abiraterone or enzalutamide. There’s a pretty good rationale for thinking that the biology of the tumor may be particularly susceptible to combining the PARP inhibitors and a novel hormone. Those combination trials with the abiraterone-enzalutamide and a PARP inhibitor combo are ongoing. They haven’t been read out, but we’re watching those with interest.

There are interesting studies that are beginning to combine the PARP inhibitors in combination with a Lutetium-177 PSMA that’s interesting. Then there are combinations with pembrolizumab and enzalutamide. There are data to support that. There are newer compounds, like the VERU-111, out there. We have some Arvinas compounds looking a little interesting in some molecularly defined subsets. A variety of new things are happening. Probably the most predictable of the ones that I can see moving up with the greatest clarity are the Lutetium-177 PSMA. There are 2 agents that are using Lutetium-177 PSMA. One is from Novartis, that’s the Lutetium-177-PSMA-617, and the second is called PNT2002, also using Lutetium. Both are moving into that post–abiraterone-enzalutamide space with no prior chemotherapy. There are also up-front trials with Lutetium-177 PSMA, as well taking the castration-sensitive space. I’m pretty sure the Lutetium-177 PSMAs are going to move up; we need the trial data to prove that.

Matthew Fowler: Lastly, what clinical pearls do you have to share with colleagues who may not see patients with prostate cancer every day?

Oliver Sartor, MD: There are several things that I’d like to emphasize. No. 1, prostate cancer isn’t breast cancer. It turns out that a lot of these individuals aren’t able to tolerate quite as much chemotherapy as some of the patients with breast cancer. They’re often patients a little older; they’re castrated. There are 4 things that you need to be very open to: 1) the idea of precision medicine; 2) the idea of the novel hormones and using them earlier when you can; 3) the possibility of taxanes, when it’s appropriate to do so; 4) the possibility of clinical trials. There’s a big evolution going on. If you don’t have a particular clinical trial, then be cognizant of a center nearby that might be able to offer a good clinical trial is something to think about as well.

Matthew Fowler: Thank you so much for your time, Dr Sartor. Thank you all for watching this CancerNetwork® OncView™ program from MJH Life Sciences™. We hope you found this to be valuable to your clinical practice.

Transcript edited for clarity.

Related Videos
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Related Content
Mary-Ellen Taplin, MD, gives her advice on how to achieve work-life balance and make other career advancements in genitourinary cancer.

Taplin’s Key to a Successful GU Career: “Always Finish” What You Start

March 28th 2024
Article

Mary-Ellen Taplin, MD, gives her advice on how to achieve work-life balance and make other career advancements in genitourinary cancer.

Oncology Peer Review On-The-Go: Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs

Oncology Peer Review On-The-Go: Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs

May 30th 2022
Podcast

Judd W. Moul, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on the treatment of a patients with evidence of prostate cancer despite multiple negative prognostic tests.

Leonard G. Gomella, MD, FACS, discusses new clinical trials that are evaluating novel targeted therapy options for those with prostate cancer.

Data Support Impact of Precision Medicine in Managing Prostate Cancer

March 12th 2024
Article

Leonard G. Gomella, MD, FACS, discusses new clinical trials that are evaluating novel targeted therapy options for those with prostate cancer.

Oncology Peer Review On-The-Go: Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer

Oncology Peer Review On-The-Go: Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer

April 26th 2022
Podcast

Muhammad Rafay Khan Niazi, MD, and Alexander Bershadskiy, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on the use of PARP inhibitors as maintenance therapy for certain patients with metastatic castration-resistant prostate cancer.

Findings from the phase 3 PROpel trial suggest that olaparib plus abiraterone acetate may help patients with metastatic castration-resistant prostate cancer live longer, according to Neal Shore, MD, FACS.

Olaparib Combo Improves Survival Vs Placebo in Metastatic CRPC

January 28th 2024
Article

Findings from the phase 3 PROpel trial suggest that olaparib plus abiraterone acetate may help patients with metastatic castration-resistant prostate cancer live longer, according to Neal Shore, MD, FACS.

Testing for HRR status prior to a diagnosis of metastatic castration-resistant prostate cancer may allow for earlier treatment and potentially greater clinical benefit with olaparib, according to Daniel J. George, MD.

Data Support Early Genetic Testing in HRR+ mCRPC Managed With Olaparib

January 27th 2024
Article

Testing for HRR status prior to a diagnosis of metastatic castration-resistant prostate cancer may allow for earlier treatment and potentially greater clinical benefit with olaparib, according to Daniel J. George, MD.